太原肛周脓肿能自愈吗(太原痣疮怎么办) (今日更新中)

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.

WASHINGTON, Nov. 7 (Xinhua) -- U.S. researchers have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.The findings, published Monday in the online edition of the Journal of Clinical Investigation, suggest that drugs targeting the brain and central nervous system could be a novel approach to treating diabetes."The brain is the body's only organ that needs a constant supply of glucose to survive, so it makes sense that it would have some say over how much glucose is produced," said study leader Meredith Hawkins, professor of medicine and director of the Global Diabetes Initiative at Yeshiva University, in a statement. "This role for the brain was demonstrated in earlier studies in rodents, but there was considerable controversy over whether the results could be applied to humans. We hope this study helps to settle the matter."In an earlier study in rodents, researchers showed that activation of potassium channels in the brain's hypothalamus sends signals to the liver that dampen its production of glucose. Those findings, published in Nature in 2005, challenged the conventional thinking that blood sugar production by the liver (the body's glucose factory) is regulated only by the pancreas (which makes insulin to metabolize glucose). But carefully performed studies on dogs, conducted at Vanderbilt University, failed to replicate the results, suggesting the Einstein findings in rodents might not be relevant to higher mammals, including humans.The current study, involving people, was aimed at resolving this controversy. Ten nondiabetic subjects were given oral diazoxide, a drug that activates potassium channels in the hypothalamus. (The drug is not used to treat diabetes.) Hormone secretion by the pancreas was controlled to ensure that any change in sugar production would only have occurred through the drug's effect on the brain. After the researchers administered the drug, blood tests revealed that patients' livers were producing significantly less glucose than before.Hawkins and her team then repeated this in rats, again giving diazoxide orally, achieving similar results. They confirmed that sufficient amounts of diazoxide crossed the blood-brain barrier to affect potassium channels in the hypothalamus. Additional experiments confirmed that diazoxide was working through the brain. Specifically, the researchers were able to completely block the effects of diazoxide by infusing a specific potassium channel blocker directly into the brain."This study confirms that the brain plays a significant role in regulating glucose production by the liver," said lead author Preeti Kishore, assistant professor of medicine. "We are now investigating whether this 'brain-to-liver' pathway is impaired in people with diabetes. If so, we may be able to restore normal glucose regulation by targeting potassium channels in the brain."

COTABATO, Philippines, Jan. 2 (Xinhua) -- The health authorities declared an outbreak of a deadly rat fever on Monday in the flood-hit areas in the southern Philippines.At least five people were already dead and as many as 200 were diagnosed in the southern city of Cagayan de Oro with leptospirosis, a fatal animal-borne disease that can result in high fever, internal bleeding and organ failure.The latest fatality, an old woman, died late Monday due to complication.Dr. Jaime Bernadas, regional health minister, said they fear the number of patients displaced by typhoon Washi could increase in the coming days.Congressman Rufus Rodriguez has called on people affected by the floods that killed over 1,200 people to avail of the government's vaccination against the deadly disease.The death toll from tropical storm Washi currently stands at 1, 258 people with many still believed missing. Washi brought massive rains, causing flooding in many areas in the Central and Southern Philippines starting last Dec. 16.

SAN FRANCISCO, Dec. 13 (Xinhua) -- Apple is in talks to acquire Israeli fabless semiconductor maker Anobit for 400 million to 500 million U.S. dollars, U.S. media reported on Tuesday.Apple is likely interested in Herzliya Pituach, Israel-based Anobit for an exclusive access to its embedded flash controllers which can significantly boost memory performance of smartphones and tablet computers, said technology news site TechCrunch, citing Calcalist, an Israeli newspaper in Hebrew which first reported the possible acquisition.Apple already uses Anobit's technology in iPhone, iPad and the MacBook Air.If the deal works out, it could be Apple's largest acquisition ever, surpassing its 404 million-dollar purchase of NeXT in 1997.It could also become Apple's first acquisition in Israel and the first with Tim Cook as the chief executive officer of the company since its iconic leader Steve Jobs passed away in early October.

LAS VEGAS, the United States, Jan. 12 (Xinhua) -- One of the most revolutionary changes for consumers that may come out of this year's International Consumer Electronics Show (CES) will not be the electronic devices themselves, but the way they are charged.Instead of using traditional cords to power mobile phones, kitchen appliances, and even vehicles, exhibits showcasing wireless power technologies offer a glimpse into the future of how individuals can charge their devices without a plug or cord.Fulton Innovation, who develops and licenses its eCoupled intelligent wireless technology, demonstrated how the technology could be applied across a variety of usage cases at home and at work.At CES, the company announced that it is releasing its next generation wireless power solutions that incorporate near-field resonant magnetic induction, allowing devices to charge without actually touching a charging surface.Additionally, it will allow power to transfer through metal surfaces, a property which had previously been unsafe to use as a surface conductor for power.While the products with integrated eCoupled capabilities currently in the marketplace focus predominantly on smartphone charging surfaces, in part due to the low-power demands of these devices, the company said there will be more applications using this technology expected to come to market in the near future.A large part of the added production scale on the consumer level is due to the standardization of the industry.In 2010, the Wireless Power Consortium (WPC) announced the finalization of the "Qi" standard, enabling interoperability for wireless charging between a power-providing device and electronics receiving power.Currently, the Qi standard is only applicable for the wireless transmission of power up to five watts, and the WPC is undertaking steps to expand this standard to deliver up to 120 watts of power.This standardization enables technology designers like Fulton Innovations to create underlying IP designs and technologies that work across a number of OEMs.The WPC currently has over 100 member companies, including Fulton Innovation, Nokia, Samsung, Haier, and Huawei Technologies.Fulton Innovation also expects to add its eCoupled technology to cars, giving automobile manufacturers the ability to install integrated charging platforms for mobile devices without additional wires or cords.Chinese auto makers Geely, Chery, Chang'an, and Dongfeng were the first to showcase cars at a major auto show featuring Qi standard charging stations during the April 2011 Shanghai Auto Show.The WPC estimates that there will be approximately five auto manufacturers who will release cars with Qi-enabled charging capabilities either late this year or early next year.

来源：资阳报